# US 12,110,151 B2 · Glass articles with mixed polymer and metal oxide coatings

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,110,151 B2
- Document ID: US12110151B2
- Status: Granted
- Kind: B2
- Application number: 18/450,538
- Filed: 2023-08-16
- Published: 2023-12-07
- Granted: 2024-10-08
- Earliest claimed: 2015-10-30
- Assignees: Corning Incorporated
- Applicants: Corning Incorporated
- Inventors: David Henry; Valerie Claudine Lacarriere
- Web page: https://patentgrep.com/patent/US12110151B2

## CPC

- B65D 23/0814: {characterised by the composition of the material}
- A61J 1/1468: {Containers characterised by specific material properties}
- B65D 1/09: Ampoules
- C03C 17/005: {Coating the outside}
- C03C 17/009: {Mixtures of organic and inorganic materials, e.g. ormosils and ormocers}
- C03C 17/256: {Coating containing TiO2}
- C03C 17/32: with synthetic or natural resins (C03C17/30 takes precedence)
- C08K 3/22: of metals
- C09D 179/08: Polyimides; Polyester-imides; Polyamide-imides; Polyamide acids or similar polyimide precursors
- C03C 2217/212: TiO2
- C03C 2217/214: Al2O3
- C03C 2217/22: ZrO2
- C03C 2218/111: by dipping, immersion
- C08G 73/1039: {comprising halogen-containing substituents}
- C08G 73/105: {with oxygen only in the diamino moiety}
- C08G 73/1071: {Wholly aromatic polyimides containing oxygen in the form of ether bonds in the main chain}
- C08K 2003/2227: {of aluminium}
- C08K 2003/2241: {Titanium dioxide}
- C08K 2003/2244: {of zirconium}
- B65D: CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- A61J: CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- C03C: CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
- C08K: Use of inorganic or non-macromolecular organic substances as compounding ingredients (paints, inks, varnishes, dyes, polishes, adhesives C09)
- C09D: COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR (cosmetics A61K; processes for applying liquids or other fluent materials to surfaces, in general, B05D; staining wood B27K5/02; glazes or vitreous enamels C03C; natural resins, French polish, drying-oils, driers, turpentine, per se, C09F; polishing compositions other than French polish, ski waxes C09G; adhesives or use of materials as adhesives C09J; materials for sealing or packing joints or covers C09K3/10; materials for stopping leaks C09K3/12; processes for the electrolytic or electrophoretic production of coatings C25D)
- C08G: MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS

## Abstract

According to one or more embodiments, a pharmaceutical package may include a glass container and a coating. The glass container may include a first surface and a second surface opposite the first surface. The first surface may be an outer surface of the glass container. The coating may be positioned over at least a portion of the first surface of the glass container. The coating may include one or more polyimide compositions and one or more metal oxide compositions. The one or more polyimide compositions and the one or more metal oxide compositions may be mixed in the coating.

## Claims

### Claim 1

A pharmaceutical package comprising:
a glass container comprising a first surface and a second surface opposite the first surface, wherein the first surface is an outer surface of the glass container; and
a coating positioned on and in direct contact with at least a portion of the first surface of the glass container, the coating comprising:
a fluorinated polyimide copolymer formed from a dianhydride monomer component and a diamine monomer component, wherein the dianhydride monomer component is 2,2-bis(3,4-dicarboxyphenyl)hexafluoropropane dianhydride (6FDA), and the diamine monomer component is selected from the group consisting of (i) 1,4-phenylenediamine (mPDA) and 1,3-phenylenediamine (pPDA); (ii) 4,4′-oxydianiline (ODA); (iii) 4,4′-(2,2,2-trifluoro(1-trifluoromethyl)ethylidene)bisbenzeneamine (4,4′-6F); (iv) 3,3′-(2,2,2-trifluoro(1-trifluoromethyl)ethylidene)bisbenzeneamine (3,3′-6F); (v) 2,3,5,6-tetramethylphenylene; and (vi) 2,2,-bis[4-(4-aminophenoxy)phenyl] hexafluoropropane (4BDAF); and
from 35.8 wt. % to 94.8 wt. % alumina;
wherein:
the fluorinated polyimide copolymer and the alumina are mixed in the coating;
the coating has a thickness of 100 nm or less;
the combination of the fluorinated polyimide copolymer and alumina comprise at least 99.5 wt. % of the coating;
the portion of the first surface of the glass container with the coating has a coefficient of friction of less than or equal to about 0.5; and
the portion of the first surface of the glass container with the coating retains the coefficient of friction of less than or equal to about 0.5 following a heat treatment at a temperature of at least about 300° C. for about 30 minutes.

### Claim 2 (depends on 1)

The pharmaceutical package of claim 1, wherein a light transmission through the pharmaceutical package is greater than or equal to about 55% of a light transmission through an uncoated glass container for each wavelength from about 400 nm to about 700 nm.

### Claim 3 (depends on 2)

The pharmaceutical package of claim 2, wherein the pharmaceutical package retains the light transmission through the pharmaceutical package of greater than or equal to about 55% of the light transmission through the uncoated glass container for each wavelength from about 400 nm to about 700 nm following a heat treatment at a temperature of at least about 250° C. for 30 minutes.

### Claim 4 (depends on 1)

The pharmaceutical package of claim 1, wherein the coating consists of the fluorinated polyimide copolymer and the alumina.

### Claim 5 (depends on 1)

The pharmaceutical package of claim 1, wherein the coating consists of the fluorinated polyimide copolymer and the alumina, and the fluorinated polyimide copolymer is 2,2-bis(3,4-dicarboxyphenyl)hexafluoropropane dianhydride-co-2,2-bis[4-(4-aminophenoxy)phenyl]hexafluoropropane (6FDA-co-4BDAF).